Figure 1.

Number needed to treat to prevent one incidence of MACE at 5 years by treatment with rosuvastatin relative to treatment with atorvastatin, according to risk group.

Notes: Smaller values indicate greater benefit. For the FRS 5%–10% group, no analysis was performed comparing rosuvastatin 20 mg with atorvastatin 80 mg. Adapted from Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. J Med Econ. 2012;15(6):1118–1129.⁴² Copyright © 2015. Adapted with permission of the author and publisher (Taylor and Francis Ltd, http://www.tandfonline.com).

Abbreviations: FRS, Framingham Risk Score; MACE, major adverse cardiovascular event; SCORE, Systematic Coronary Risk Evaluation.